Due to current supply constraints for the new RSV prophylaxis agent Beyfortus (nirsevimab), the MO HealthNet Division (MHD) will allow up to five doses of Synagis (palivizumab) for the 2023 – 2024 RSV season. Participants who meet the clinical edit requirements, including age restrictions, may receive approval for up to five doses to start the 2023 - 2024 RSV season, depending on the requested date for the initial prior authorization. MHD will automatically extend prior authorization requests for Synagis that were previously approved from 10/31/2023 – 11/7/2023 for only two doses to up to five doses to cover the full season.
MHD recommends pharmacies coordinate with providers to ensure a scheduled appointment exists with their patient to administer Synagis before sending doses to reduce abandoned medication. MHD will evaluate claims to ensure there is no excessive waste.
Providers with questions may call MO HealthNet at 800-392-8030.